Overview
of the human reproductive technologies market
The
World Health Organization (WHO) reported in 2010 that almost 1.9% of
the global female population between the age of 20 years and 44 years
were unable to conceive their first child, while 10.9% of the women
who had already given birth to a child faced problems conceiving the
subsequent time. The globally increasing prevalence of infertility
will propel the global human reproductive technologies market
substantially.
Based
on geography, the global human reproductive technologies market can
be segmented into North America, Europe, Asia Pacific, and Rest of
the World (RoW). Among the key geographic segments, North America
dominates the market, followed by Europe. High incidence of obesity,
paradigm shift in lifestyle choices, and increasing age of conception
are key factors driving the human reproductive technologies market in
North America.
Browse
Market Research
Report:
http://www.transparencymarketresearch.com/human-reproductive-technologies-market.html
http://www.transparencymarketresearch.com/human-reproductive-technologies-market.html
Human
reproductive technologies include procedures and therapies for
conceiving or controlling pregnancy by means of artificial and/or
semi artificial medical solutions. Reproductive technologies are used
to treat infertility problems in males as well as in females. Since
the last decade, a remarkable prevalence of infertility has been
observed worldwide and its morbidity rate is rapidly growing. Changes
in lifestyle such as delay in bearing the first child, use of
contraceptive pills, increased alcohol consumption and smoking are
some of the factors leading to increase in the infertility rate
globally, due to which the human reproductive technologies market is
experiencing rise in demand. The World Health Organization (WHO)
reported that in 2010, approximately 1.9% of women aged between 20
years and 44 years were unable to have their first child and 10.5% of
women who had already conceived were unable to conceive for the
subsequent times. Thus, high global infertility rates will continue
to provide newer growth opportunities to this market. Some other
factors contributing to the growth of the human reproductive
technologies market include increasing morbidity rate of infertility
in both males and females, rise in awareness about the available
technologies for treating problems related to reproduction, rising
prevalence of unwanted pregnancies, and overall advancement in the
available technologies to control reproduction.
Human
reproductive technologies are mainly categorized on the basis of
infertility treatments and contraceptive technologies. The
infertility drugs market is analyzed based on the big seven brands
(by sales) such as, Gonal-f, Follistim AQ, AndroGel, Testim, Viagra,
Cialis and Levitra/Staxyn. Viagra, Gonal-f and AndroGel are the major
drugs in their respective drug classes, which are preferred majorly
for treating different causes of infertility. Further, the human
reproductive technologies market is analyzed by various infertility
treatment procedures which is led by the intrauterine insemination
(IUI) procedure owing to low procedural cost and less complexity in
performing the procedure.
Fill
the form for an exclusive sample of this report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1876
Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Browse market research blog: https://tmrresearch.blogspot.com/
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Browse market research blog: https://tmrresearch.blogspot.com/

No comments:
Post a Comment